ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $39.62M rose 21.1% year over year, ahead of the +2.2% change in trailing-twelve-month operating expenses. Sequentially, it rose 15.7% from the prior quarter. Over 3 fiscal years it compounded at +15.6% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +21.1% holds above the trailing-twelve-month pace of +2.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 141.78M USD
- Year-over-year change
- -0.0%
- 4-year CAGR
- +15.8%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 141.78M | -0.0% |
| FY2024 | 2024-12-31 | 141.79M | +29.2% |
| FY2023 | 2023-12-31 | 109.75M | +19.6% |
| FY2022 | 2022-12-31 | 91.77M | +16.4% |
| FY2021 | 2021-12-31 | 78.87M | — |
Operating Expenses vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's LTM Mar 2026 operating expenses of $149.59M is the 7th highest of the 11 companies compared; the peer median is $162.78M.
- Its year-over-year change of +2.2% is the 10th highest of 11, against a peer median of +27.9%.
- Over three fiscal years its annual growth of +15.6% compares with a peer median of +30.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $436.26M | +12.8% | +42.4% | 200.9% | |
| LTM Jun 2026 | $297.23M | +30.0% | +30.7% | 174.9% | |
| LTM Mar 2026 | $212.38M | +50.5% | +37.4% | 428.3% | |
| LTM Mar 2026 | $173.51M | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $168.69M | +127.4% | +30.3% | 780.5% | |
| LTM Mar 2026 | $156.87M | +11.7% | +68.8% | — | |
| LTM Mar 2026 | $149.59M | +2.2% | +15.6% | — | |
| LTM Mar 2026 | $142.77M | +25.7% | +31.1% | — | |
| LTM Sep 2026 | $135.32M | +20.5% | +45.5% | — | |
| LTM Mar 2026 | $47.9M | +53.4% | +9.6% | — | |
| LTM Mar 2026 | $28.27M | +34.5% | +12.8% | — | |
| Peer median (excluding ORIC) | $162.78M | +27.9% | +30.9% | 200.9% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.03M | 1.11M | 1.22M |
| Gross Profit | 0 | 0 | (1.03M) | (1.11M) | (1.22M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 56.86M | 61.68M | 85.17M | 114.07M | 109.82M |
| Selling, General & Admin | 22.01M | 25.09M | 25.61M | 28.82M | 33.19M |
| Operating Expenses | 78.87M | 91.77M | 109.75M | 141.79M | 141.78M |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| EBITDA | (77.82M) | (85.8M) | (99.67M) | (126.74M) | (128.25M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (78.87M) | (91.77M) | (110.78M) | (142.9M) | (143M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 141K | 2.65M | 10.08M | 0 | 0 |
| Interest Expense | 0 | 2.65M | 0 | 0 | 0 |
| Other Income / Expenses | 156K | 2.65M | 10.08M | 15.05M | 13.54M |
| Income Before Tax | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| EPS (Diluted) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| Weighted Avg Shares | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
| Weighted Avg Shares (Diluted) | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.